- Conditions
- Scleroderma, Diffuse
- Interventions
- rapcabtagene autoleucel, rituximab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Rapcabtagene autoleucel, Active Comparator Option
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more
- Conditions
- Lupus Erythematosus, Systemic, Lupus Nephritis
- Interventions
- rapcabtagene autoleucel
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Bernardino, California • San Francisco, California + 11 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
- Interventions
- Rapcabtagene autoleucel single agent, Ibrutinib
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Tampa, Florida + 8 more
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more